WallStreetZen

NASDAQ: NVAX
Novavax Inc Stock Forecast, Predictions & Price Target

Analyst price target for NVAX

Based on 7 analysts offering 12 month price targets for Novavax Inc.
Min Forecast
$105.00-41.63%
Avg Forecast
$233.71+29.92%
Max Forecast
$397.00+120.69%

Should I buy or sell NVAX stock?

Buy
Strong Buy
3 analysts 42.86%
Buy
2 analysts 28.57%
Hold
1 analysts 14.29%
Sell
0 analysts 0%
Strong Sell
1 analysts 14.29%

NVAX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDate
Charles Duncan
Cantor Fitzgerald
Strong BuyMaintains$272.00+51.20%2021-06-15
Mayank Mamtani
B. Riley
Strong BuyMaintains$397.00+120.69%2021-02-18
Kelechi Chikere
Jefferies
Strong BuyInitiates Coverage On$200.00+11.18%2020-12-14
Vernon Bernardino
HC Wainwright & Co.
BuyMaintains$294.00+63.43%2021-05-12
Anonymous
HC Wainwright & Co.
BuyMaintains$207.00+15.07%2020-11-17
Eric Joseph
JP Morgan
HoldDowngrades$161.00-10.50%2021-05-12
Michael Higgins
Ladenburg Thalmann
Strong SellDowngrades$105.00-41.63%2020-08-05

1 of 1

Forecast return on equity

Is NVAX forecast to generate an efficient return?
Company
242.9%
Industry
4.87%
Market
61.45%
NVAX's Return on Equity is forecast to be high in 3 years (242.9%); analysts are confident in the firm's ability to efficiently generate return on equity
Forecast

Forecast return on assets

Is NVAX forecast to generate an efficient return on assets?
Company
96.77%
Industry
7.64%
Market
19.05%
NVAX is forecast to generate higher Return on Assets (96.77%) than the US Biotechnology industry average (7.64%)
Forecast

NVAX earnings per share forecast

What is NVAX's earnings per share in the next 3 years based on estimates from 5 analysts?
Avg 1 year Forecast
-$6.42-31.99%
Avg 2 year Forecast
$30.21-420.04%
Avg 3 year Forecast
$26.93-385.28%

NVAX revenue forecast

What is NVAX's revenue in the next 3 years based on estimates from 4 analysts?
Avg 1 year Forecast
$1.9B+111.19%
Avg 2 year Forecast
$4.9B+438.06%
Avg 3 year Forecast
$4.4B+375.79%
NVAX's revenue is forecast to grow at an exceptional rate of 77.34% per year
Forecast

NVAX revenue growth forecast

How is NVAX forecast to perform vs Biotechnology companies and vs the US market?
Company
77.34%
Industry
54.18%
Market
14.6%
NVAX's revenues are forecast to grow faster (77.34% per year) than the US Biotechnology industry average (54.18%)
Forecast
NVAX's revenues are forecast to grow faster (77.34% per year) than the US market average (14.6%)
Forecast

Novavax Stock Forecast FAQ

Is Novavax Stock a good buy in 2021, according to Wall Street analysts?

The consensus among 7 Wall Street analysts covering (NASDAQ: NVAX) stock is to Buy NVAX stock.

Out of 7 analysts, 3 (42.86%) are recommending NVAX as a Strong Buy, 2 (28.57%) are recommending NVAX as a Buy, 1 (14.29%) are recommending NVAX as a Hold, 0 (0%) are recommending NVAX as a Sell, and 1 (14.29%) are recommending NVAX as a Strong Sell.

What is NVAX's earnings growth forecast for 2021-2023?

(NASDAQ: NVAX) Novavax's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 28.73%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 19.61%.

Novavax's earnings in 2021 is -$615,114,000.On average, 5 Wall Street analysts forecast NVAX's earnings for 2021 to be $-475,686,273, with the lowest NVAX earnings forecast at $-1,510,044,585, and the highest NVAX earnings forecast at $142,261,315. On average, 5 Wall Street analysts forecast NVAX's earnings for 2022 to be $2,238,541,070, with the lowest NVAX earnings forecast at $850,604,114, and the highest NVAX earnings forecast at $3,629,886,371.

In 2023, NVAX is forecast to generate $1,995,363,135 in earnings, with the lowest earnings forecast at $1,081,037,807 and the highest earnings forecast at $3,522,449,440.

What is NVAX's revenue growth forecast for 2021-2023?

(NASDAQ: NVAX) Novavax's forecast annual revenue growth rate of 77.34% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 54.18%, and and it is also forecast to beat the US market's average forecast revenue growth rate of 14.6%.

Novavax's revenue in 2021 is $919,450,000.On average, 4 Wall Street analysts forecast NVAX's revenue for 2021 to be $143,874,351,050, with the lowest NVAX revenue forecast at $66,483,454,637, and the highest NVAX revenue forecast at $206,182,584,275. On average, 4 Wall Street analysts forecast NVAX's revenue for 2022 to be $366,558,136,471, with the lowest NVAX revenue forecast at $207,575,559,653, and the highest NVAX revenue forecast at $589,028,529,920.

In 2023, NVAX is forecast to generate $324,134,997,240 in revenue, with the lowest revenue forecast at $153,105,776,707 and the highest revenue forecast at $562,243,391,667.

What is NVAX's forecast return on assets (ROA) for 2021-2024?

(NASDAQ: NVAX) forecast ROA is 96.77%, which is higher than the forecast US Biotechnology industry average of 7.64%.

What is NVAX's Price Target?

According to 7 Wall Street analysts that have issued a 1 year NVAX price target, the average NVAX price target is $233.71, with the highest NVAX stock price forecast at $397.00 and the lowest NVAX stock price forecast at $105.00.

On average, Wall Street analysts predict that Novavax's share price could stay at $233.71 by Jun 15, 2022. The average Novavax stock price prediction forecasts a potential downside of N/A from the current NVAX share price of $179.89.

What is NVAX's Earnings Per Share (EPS) forecast for 2021-2023?

(NASDAQ: NVAX) Novavax's current Earnings Per Share (EPS) is -$9.44. On average, analysts forecast that NVAX's EPS will be $-6.42 for 2021, with the lowest EPS forecast at $-20.38, and the highest EPS forecast at $1.92. On average, analysts forecast that NVAX's EPS will be $30.21 for 2022, with the lowest EPS forecast at $11.48, and the highest EPS forecast at $48.99. In 2023, NVAX's EPS is forecast to hit $26.93 (min: $14.59, max: $47.54).

What is NVAX's forecast return on equity (ROE) for 2021-2024?

(NASDAQ: NVAX) forecast ROE is 242.9%, which is considered strong.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.